Parmax Pharma Limited (PARMAX.BO)
INR 46.0
(4.93%)
INR 46.0
(4.93%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 154.24 Million | 182.51 Million | 262.04 Million | 209.34 Million |
| Cost of Revenue | 54.92 Million | 105.33 Million | 174.45 Million | 147.1 Million |
| Gross Profit | 99.31 Million | 77.17 Million | 87.59 Million | 62.23 Million |
| Operating Expenses | 99.31 Million | 66.83 Million | 67.83 Million | 49.94 Million |
| Selling, General and Administrative Expenses | 8.57 Million | 9.26 Million | 8.87 Million | 8.02 Million |
| Research and Development Expenses | - | - | - | - |
| Other Expenses | 90.73 Million | 318.73 Thousand | 217.27 Thousand | 220.26 Thousand |
| Cost and Expenses | 154.24 Million | 172.17 Million | 242.28 Million | 197.05 Million |
| Operating Income | 3.75 Million | 10.59 Million | 20.32 Million | 13.16 Million |
| Interest Expense | 3.81 Million | 3.54 Million | 3.6 Million | 1.17 Million |
| Income Tax Expense | 1.5 Million | 1.61 Million | 4.54 Million | 3.01 Million |
| Earnings before Tax | 461.23 Thousand | 3.03 Million | 12.08 Million | 7.3 Million |
| Net Income | -1.04 Million | 1.41 Million | 7.54 Million | 4.28 Million |
| Earnings Per Share Basic | -0.28 | 0.38 | 2.00 | 1.15 |
| Earnings Per Share Diluted | -0.28 | 0.38 | 2.00 | 1.15 |
| Weighted Average Shares Outstanding | 3.71 Million | 3.74 Million | 3.74 Million | 3.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 3.71 Million | 3.74 Million | 3.74 Million | 3.74 Million |
| Gross Margin | 0.64 | 0.42 | 0.33 | 0.30 |
| EBIT Margin | 0.15 | 0.16 | 0.15 | 0.11 |
| Profit Margin | -0.01 | 0.01 | 0.03 | 0.02 |
| EBITDA | 22.93 Million | 29.91 Million | 39.73 Million | 23.23 Million |
| Earnings Before Tax Margin | 0.02 | 0.06 | 0.08 | 0.06 |
| Breakdown | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2022 FY | 2023 Q1 | 2022 Q4 |
|---|---|---|---|---|---|---|
| Revenue | 13.27 Million | 40.68 Million | 14 Million | 154.24 Million | 63.81 Million | 53.53 Million |
| Cost of Revenue | 6.24 Million | 27.34 Million | 4.28 Million | 88.33 Million | 69.38 Million | 5.81 Million |
| Gross Profit | 7.02 Million | 13.33 Million | 9.71 Million | 65.9 Million | -5.56 Million | 47.71 Million |
| Operating Expenses | 23.1 Million | 25.29 Million | 19.43 Million | 57.61 Million | -13.72 Million | 29.3 Million |
| Selling, General and Administrative Expenses | - | - | - | - | - | - |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 109.48 Thousand | 93.34 Thousand | 136.95 Thousand | 240.6 Thousand | -7456.00 | 86.85 Thousand |
| Cost and Expenses | 29.34 Million | 52.64 Million | 23.71 Million | 145.95 Million | 55.66 Million | 35.11 Million |
| Operating Income | -15.96 Million | -11.87 Million | -9.58 Million | 8.24 Million | 7.86 Million | 18.49 Million |
| Interest Expense | 1.56 Million | 1.81 Million | 1.21 Million | 3.81 Million | 669.46 Thousand | 1.06 Million |
| Income Tax Expense | - | - | - | 1.5 Million | 1.5 Million | - |
| Earnings before Tax | -17.52 Million | -13.68 Million | -11.78 Million | 461.23 Thousand | 3.23 Million | 17.43 Million |
| Net Income | -17.52 Million | -13.68 Million | -11.78 Million | -1.04 Million | 1.72 Million | 17.43 Million |
| Earnings Per Share Basic | -4.68 | -3.66 | -3.15 | - | 0.46 | 4.66 |
| Earnings Per Share Diluted | -4.68 | -3.66 | -3.15 | - | 0.46 | 4.66 |
| Weighted Average Shares Outstanding | 3.74 Million | 3.73 Million | 3.74 Million | 3.74 Million | 3.74 Million | 3.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 3.74 Million | 3.73 Million | 3.74 Million | 3.74 Million | 3.74 Million | 3.74 Million |
| Gross Margin | 0.53 | 0.33 | 0.69 | 0.43 | -0.09 | 0.89 |
| EBIT Margin | -0.86 | -0.19 | -0.39 | - | 0.20 | 0.43 |
| Profit Margin | -1.32 | -0.34 | -0.84 | -0.01 | 0.03 | 0.33 |
| EBITDA | -11.42 Million | -7.54 Million | -5.39 Million | - | 12.59 Million | 23.27 Million |
| Earnings Before Tax Margin | -1.20 | -0.29 | -0.68 | 0.05 | 0.12 | 0.35 |
BRYFF
LGIH
HRL
BUAH
0764
5541